|
US5192537A
(en)
*
|
1984-03-30 |
1993-03-09 |
Cellcor Inc. |
Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
|
|
US5766920A
(en)
*
|
1982-08-11 |
1998-06-16 |
Cellcor, Inc. |
Ex vivo activation of immune cells
|
|
IL69686A
(en)
*
|
1983-09-11 |
1988-03-31 |
Yeda Res & Dev |
Compositions containing cell membrane proteins and process for their preparation
|
|
US4883662A
(en)
*
|
1984-04-10 |
1989-11-28 |
Clinical Biotechnologies, Inc. |
Method of increasing natural killer cell population of cancer patients
|
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
|
US5308626A
(en)
*
|
1985-06-28 |
1994-05-03 |
Toni N. Mariani |
Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
|
|
US4902288A
(en)
*
|
1985-12-03 |
1990-02-20 |
Marylou Ingram |
Implantable immunotherapy system using stimulated cells
|
|
WO1987006610A1
(en)
*
|
1986-04-28 |
1987-11-05 |
Endotronics, Inc. |
Method of culturing leukocytes
|
|
US5002879A
(en)
*
|
1986-05-06 |
1991-03-26 |
Merrell Dow Pharmaceuticals |
Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
|
|
US4937194A
(en)
*
|
1986-05-12 |
1990-06-26 |
Baxter International Inc. |
Method for metering nutrient media to cell culture containers
|
|
US4829002A
(en)
*
|
1986-05-12 |
1989-05-09 |
Baxter International Inc. |
System for metering nutrient media to cell culture containers and method
|
|
US4971795A
(en)
*
|
1986-07-08 |
1990-11-20 |
Biomira, Inc. |
Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
|
|
AU7873187A
(en)
*
|
1986-08-08 |
1988-02-24 |
University Of Minnesota |
Method of culturing leukocytes
|
|
JPS63119428A
(ja)
*
|
1986-09-19 |
1988-05-24 |
オンコーゲン |
エイズの処置のための養子免疫療法の方法
|
|
US4861589A
(en)
*
|
1987-03-23 |
1989-08-29 |
Trustees Of Boston University |
Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
|
|
US4808151A
(en)
*
|
1987-04-27 |
1989-02-28 |
E. I. Du Pont De Nemours And Company |
Simplified method for the preparation of human lymphokine activated killer cells
|
|
JPH02501534A
(ja)
*
|
1987-09-22 |
1990-05-31 |
バンデンバーク・アーサー・アレン |
細胞表面決定基の発現および機能を選択的に調節する方法およびこれによりつくられる新規な人間細胞の産生
|
|
US5041289A
(en)
*
|
1987-11-13 |
1991-08-20 |
Becton Dickinson And Company |
Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
|
|
AU2925789A
(en)
*
|
1987-12-17 |
1989-07-19 |
Browning's Clinical Pathology Services Limited |
Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
|
|
US5057423A
(en)
*
|
1987-12-18 |
1991-10-15 |
University Of Pittsburgh |
Method for the preparation of pure LAK-active lymphocytes
|
|
US5066489A
(en)
*
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
US5120525A
(en)
*
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
|
CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
|
US5278143A
(en)
*
|
1988-04-25 |
1994-01-11 |
Trustees Of Boston University |
Prophylactic and therapeutic methods for treating interleukin-mediated edemas
|
|
FR2635527B1
(fr)
*
|
1988-07-28 |
1992-06-12 |
Roussel Uclaf |
Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
|
|
JP2955314B2
(ja)
*
|
1988-10-27 |
1999-10-04 |
リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ |
Ｉｌ―２含有リポソーム免疫アジュバント
|
|
GB8826298D0
(en)
*
|
1988-11-10 |
1988-12-14 |
Williams N S |
Production of lak cells compositions containing them & their use in cancer therapy
|
|
CA1340565C
(en)
*
|
1989-06-29 |
1999-05-25 |
Thomas B. Okarma |
Device and process for cell capture and recovery
|
|
US6143508A
(en)
*
|
1989-06-29 |
2000-11-07 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Device and process for cell capture and recovery
|
|
US5108760A
(en)
*
|
1989-07-21 |
1992-04-28 |
Terumo Corporation |
Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
|
|
US5126132A
(en)
*
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
AU652725B2
(en)
*
|
1989-09-14 |
1994-09-08 |
Cellco, Inc. |
Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
|
|
JPH0728732B2
(ja)
*
|
1990-04-17 |
1995-04-05 |
日本石油株式会社 |
動物細胞増殖促進剤及び無血清培地
|
|
US5344755A
(en)
*
|
1990-04-21 |
1994-09-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals
|
|
US5766897A
(en)
*
|
1990-06-21 |
1998-06-16 |
Incyte Pharmaceuticals, Inc. |
Cysteine-pegylated proteins
|
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
|
US5229115A
(en)
*
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
DK0567586T3
(da)
*
|
1991-01-16 |
1995-12-04 |
Schering Corp |
Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
|
|
US5851828A
(en)
*
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
US5912170A
(en)
*
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
JPH06506465A
(ja)
*
|
1991-04-05 |
1994-07-21 |
リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ |
細胞サブセットの欠落／陽性選択による免疫細胞の免疫療法活性の増強方法
|
|
US5725855A
(en)
*
|
1991-04-05 |
1998-03-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
|
|
US5199942A
(en)
*
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
IE922233A1
(en)
*
|
1991-07-10 |
1993-01-13 |
Augusto C Ochoa |
Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
|
|
JP4111463B2
(ja)
*
|
1991-08-23 |
2008-07-02 |
ボード・オブ・リージェンツ・オブ・ジ・ユニバーシティ・オブ・ネブラスカ |
細胞リプログラミング方法及び組成物
|
|
AU3423493A
(en)
*
|
1991-12-31 |
1993-07-28 |
Zymogenetics Inc. |
Methods and compositions for reducing blood loss
|
|
US5296353A
(en)
*
|
1992-04-06 |
1994-03-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Evaluation and treatment of patients with progessive immunosuppression
|
|
US5556763A
(en)
*
|
1992-04-06 |
1996-09-17 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Evaluation and treatment of patients with progressive immunosuppression
|
|
US5229109A
(en)
*
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
TW381026B
(en)
*
|
1993-01-13 |
2000-02-01 |
Schering Corp |
Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
|
|
US5670352A
(en)
*
|
1993-03-18 |
1997-09-23 |
Behringwerke Aktiengesellschaft |
Stable growth transformation of human T-lymphocytes by Herpesvirus saimiri (H. saimiri) subgroup C
|
|
DE69433013T2
(de)
*
|
1993-05-27 |
2004-06-03 |
Entremed, Inc. |
Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
|
|
US5536642A
(en)
*
|
1993-09-09 |
1996-07-16 |
Barbera-Guillem; Emilio |
Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
|
|
US5750119A
(en)
|
1994-01-13 |
1998-05-12 |
Mount Sinai School Of Medicine Of The City University Of New York |
Immunotherapeutic stress protein-peptide complexes against cancer
|
|
US5997873A
(en)
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
|
US5961979A
(en)
*
|
1994-03-16 |
1999-10-05 |
Mount Sinai School Of Medicine Of The City University Of New York |
Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
|
|
IL112969A
(en)
*
|
1994-03-17 |
2001-05-20 |
Baxter Int |
Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
|
|
US5709995A
(en)
*
|
1994-03-17 |
1998-01-20 |
The Scripps Research Institute |
Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
|
|
EP0775197A1
(de)
*
|
1994-08-08 |
1997-05-28 |
Maxim Pharmaceuticals, Inc. |
Verstärkte aktivierung von natürlicher killerzellen durch verwendung von einem fängern oder hemmern des wasserstoffperoxids
|
|
US6045802A
(en)
*
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
|
JP3907698B2
(ja)
*
|
1994-10-03 |
2007-04-18 |
アメリカ合衆国 |
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
|
|
US5935847A
(en)
*
|
1994-10-28 |
1999-08-10 |
Baxter International Inc. |
Multilayer gas-permeable container for the culture of adherent and non-adherent cells
|
|
US6297046B1
(en)
|
1994-10-28 |
2001-10-02 |
Baxter International Inc. |
Multilayer gas-permeable container for the culture of adherent and non-adherent cells
|
|
US7361332B2
(en)
|
1995-03-17 |
2008-04-22 |
The Regents Of The University Of California |
Treating tumors using implants comprising combinations of allogeneic cells
|
|
US6024220A
(en)
*
|
1995-06-07 |
2000-02-15 |
Baxter International Inc. |
Encapsulated seam for multilayer materials
|
|
US6391404B1
(en)
|
1995-06-07 |
2002-05-21 |
Baxter International Inc. |
Coextruded multilayer film materials and containers made therefrom
|
|
US20020182730A1
(en)
*
|
1995-07-26 |
2002-12-05 |
Micheal L. Gruenberg |
Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
|
|
US5627070A
(en)
*
|
1995-07-26 |
1997-05-06 |
Celltherapy, Inc. |
Cell growing device for in vitro cell population expansion
|
|
US5837251A
(en)
*
|
1995-09-13 |
1998-11-17 |
Fordham University |
Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
|
|
US5985270A
(en)
*
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
|
US5935576A
(en)
*
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
|
ES2203782T3
(es)
|
1996-01-17 |
2004-04-16 |
Imperial College Innovations Limited |
Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
|
|
EP0979101B1
(de)
|
1996-07-03 |
2010-10-27 |
Merial, Inc. |
Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
|
|
US6130087A
(en)
*
|
1996-10-07 |
2000-10-10 |
Fordham University |
Methods for generating cytotoxic T cells in vitro
|
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
|
US5830464A
(en)
|
1997-02-07 |
1998-11-03 |
Fordham University |
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
|
|
US5981472A
(en)
*
|
1997-02-21 |
1999-11-09 |
Dx/Ibr Corporation |
Methods for treating diseases
|
|
US6884414B1
(en)
|
1997-04-30 |
2005-04-26 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
|
|
US6872518B2
(en)
*
|
1997-09-22 |
2005-03-29 |
University Of Rochester |
Methods for selecting polynucleotides encoding T cell epitopes
|
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
|
EP1054683B1
(de)
*
|
1998-02-20 |
2007-04-11 |
University Of Miami |
Modifizierter hitzeschockprotein/peptidantigen komplex
|
|
AU2873999A
(en)
|
1998-02-24 |
1999-09-06 |
Sisters Of Providence In Oregon |
Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
|
|
US6790604B1
(en)
|
1998-05-12 |
2004-09-14 |
Stefan A. Cohen |
Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
|
|
JP2002518346A
(ja)
|
1998-06-17 |
2002-06-25 |
エピミューン， インコーポレイテッド |
Ｈｌａ結合ペプチドおよびそれらの用途
|
|
US6168785B1
(en)
*
|
1998-07-16 |
2001-01-02 |
Institut Pasteur |
Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
|
|
US6929791B2
(en)
|
1998-07-16 |
2005-08-16 |
Institut Pasteur |
Peptides of IL-2 and derivatives thereof
|
|
US20020092987A1
(en)
*
|
1998-09-05 |
2002-07-18 |
Taehee Cho |
Photo detect device using quantum dots and materialization method thereof
|
|
US6451316B1
(en)
|
1998-10-05 |
2002-09-17 |
University Of Conneticut Health Center |
Methods for generating antigen-reactive T cells in vitro
|
|
US7807377B2
(en)
|
1998-10-20 |
2010-10-05 |
Salvatore Albani |
Method of isolating antigen-specific T cells employing artificial antigen presenting cells
|
|
DE69942100D1
(de)
|
1998-10-20 |
2010-04-15 |
Androclus Technologies S R L I |
Künstliche antigen-spezifischen zellen und zugehörige verfahren
|
|
US6787154B2
(en)
*
|
1998-10-20 |
2004-09-07 |
Salvatore Albani |
Artificial antigen presenting cells
|
|
US6656471B1
(en)
|
1998-11-17 |
2003-12-02 |
Board Of Regents, The University Of Texas System |
HIV-specific T-cell induction
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
RU2263118C2
(ru)
|
1999-08-09 |
2005-10-27 |
Лексиген Фармасьютикэлс Корп. |
Комплексы антител с несколькими цитокинами
|
|
US20040266834A1
(en)
*
|
1999-10-14 |
2004-12-30 |
Copland John A. |
Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
US20030194696A1
(en)
*
|
2000-03-28 |
2003-10-16 |
University Of Rochester |
Methods of producing a library and methods of selecting polynucleotides of interest
|
|
WO2001072995A2
(en)
*
|
2000-03-28 |
2001-10-04 |
University Of Rochester |
Methods of producing a library and methods of selecting polynucletides
|
|
AU6669401A
(en)
|
2000-06-02 |
2001-12-11 |
Univ Connecticut Health Ct |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
|
US7517526B2
(en)
|
2000-06-29 |
2009-04-14 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
EP1455816A4
(de)
|
2000-10-19 |
2007-03-28 |
Epimmune Inc |
Hla-klasse-i- und -ii-bindende peptide und deren verwendung
|
|
CA2436903A1
(en)
*
|
2000-11-30 |
2002-06-06 |
Imperial College Innovations Limited |
Immunotherapeutic methods and molecules
|
|
US7919467B2
(en)
*
|
2000-12-04 |
2011-04-05 |
Immunotope, Inc. |
Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
EP2295575A3
(de)
|
2000-12-04 |
2011-07-06 |
Immunotope, Inc. |
Zytotoxische T-Lymphozyten induzierende Immunogene zur Prävention, Behandlung und Diagnose von Krebs
|
|
US6855925B2
(en)
*
|
2001-02-14 |
2005-02-15 |
Picoliter Inc. |
Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
|
|
PT1366067E
(pt)
|
2001-03-07 |
2012-11-29 |
Merck Patent Gmbh |
Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
|
|
FR2821947B1
(fr)
*
|
2001-03-12 |
2003-05-16 |
Canon Kk |
Procede et dispositif de validation de parametres definissant une image
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
DE60239454D1
(de)
|
2001-05-03 |
2011-04-28 |
Merck Patent Gmbh |
Rekombinanter, tumorspezifischer antikörper und dessen verwendung
|
|
US7666581B2
(en)
*
|
2001-08-20 |
2010-02-23 |
University Of Connecticut Health Center |
Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease
|
|
US20030134341A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Medcell Biologics, Llc. |
Th1 cell adoptive immunotherapy
|
|
US20030175242A1
(en)
*
|
2001-09-17 |
2003-09-18 |
Micheal Gruenberg |
Cell therapy system
|
|
US20030134415A1
(en)
*
|
2001-09-19 |
2003-07-17 |
Gruenberg Micheal L. |
Th1 cell adoptive immunotherapy
|
|
RU2201762C1
(ru)
*
|
2001-10-09 |
2003-04-10 |
Свадовский Александр Игоревич |
Способ лечения внутримозговой опухоли головного мозга
|
|
JP2005509434A
(ja)
*
|
2001-11-22 |
2005-04-14 |
メディジーンズ |
インターロイキン−２遺伝子が導入されたリンフォカイン活性キラー細胞
|
|
AU2002357784B2
(en)
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
|
US20040236514A1
(en)
*
|
2001-12-13 |
2004-11-25 |
Lee Stephen C. |
Controlling distribution of epitopes in polypeptide sequences
|
|
US20030175272A1
(en)
*
|
2002-03-07 |
2003-09-18 |
Medcell Biologics, Inc. |
Re-activated T-cells for adoptive immunotherapy
|
|
CN100418981C
(zh)
|
2002-06-10 |
2008-09-17 |
瓦西尼斯公司 |
在乳腺癌和膀胱癌中差异表达的基因及编码多肽
|
|
AU2003265948B8
(en)
*
|
2002-09-06 |
2009-09-03 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
|
US9809654B2
(en)
*
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
|
ES2346205T3
(es)
|
2002-12-17 |
2010-10-13 |
Merck Patent Gmbh |
Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
|
|
RU2324493C2
(ru)
*
|
2003-02-20 |
2008-05-20 |
Юниверсити Оф Коннектикут Хелт Сентер |
Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
|
|
US7638122B2
(en)
*
|
2003-03-07 |
2009-12-29 |
University Of South Florida |
Stat3 antagonists and their use as vaccines against cancer
|
|
US20040242676A1
(en)
*
|
2003-05-30 |
2004-12-02 |
Alessi Thomas R. |
Method of mitigating the adverse effects of IL-2
|
|
WO2005044982A2
(en)
|
2003-09-05 |
2005-05-19 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
US8541002B2
(en)
*
|
2003-09-12 |
2013-09-24 |
Agenus Inc. |
Vaccine for treatment and prevention of herpes simplex virus infection
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
ES2616337T3
(es)
|
2003-12-12 |
2017-06-12 |
Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors |
Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1
|
|
US7838503B2
(en)
*
|
2005-06-15 |
2010-11-23 |
Children's Medical Center Corporation |
Methods for extending the replicative lifespan of cells
|
|
EP1937307A4
(de)
*
|
2005-09-14 |
2009-05-13 |
Hutchinson Fred Cancer Res |
Spezifische entfernung von aktivierten immunzellen
|
|
US20070248628A1
(en)
*
|
2005-12-06 |
2007-10-25 |
Keller Lorraine H |
Immunogens in cancer stem cells
|
|
EP2368570A3
(de)
|
2006-01-18 |
2012-05-02 |
University Of Chicago |
Zusammensetzungen und Verfahren in Verbindung mit Stayphylokokken-Bakterienproteinen
|
|
RU2447900C2
(ru)
|
2006-03-01 |
2012-04-20 |
Янссен Фармацевтика Н.В. |
Лечение рака, комбинирующее лимфоистощающее вещество с цтл и цитокинами
|
|
US20080107668A1
(en)
*
|
2006-08-30 |
2008-05-08 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
CA2700573C
(en)
|
2006-09-26 |
2016-11-22 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
|
WO2008039969A2
(en)
|
2006-09-28 |
2008-04-03 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
|
BRPI0720342A2
(pt)
|
2006-10-04 |
2018-09-18 |
Janssen Pharmaceutica N.V. |
preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
EP2112930B1
(de)
*
|
2007-02-21 |
2017-01-11 |
Vaccinex, Inc. |
Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
|
|
EP2155241A4
(de)
*
|
2007-05-04 |
2010-06-02 |
Boris Skurkovich |
Verhinderung von krebs durch immunisierung
|
|
US9181329B2
(en)
|
2007-08-31 |
2015-11-10 |
The University Of Chicago |
Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
|
|
AU2008292897B2
(en)
*
|
2007-08-31 |
2015-01-22 |
University Of Chicago |
Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
|
|
US9090875B2
(en)
|
2008-01-29 |
2015-07-28 |
Fred Hutchinson Cancer Research Center |
Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
|
|
DK2257301T3
(da)
|
2008-03-03 |
2014-04-28 |
Univ Miami |
Immunterapi baseret på allogene cancerceller.
|
|
KR20110017356A
(ko)
|
2008-03-20 |
2011-02-21 |
유니버시티 오브 마이애미 |
열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
|
|
EP2300023A2
(de)
*
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Mikroorganismen zur prävention und behandlung von neoplasien neben einer zelltherapie
|
|
WO2010014304A1
(en)
*
|
2008-07-29 |
2010-02-04 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
|
DK2328923T3
(en)
*
|
2008-09-02 |
2016-03-21 |
Cedars Sinai Medical Center |
CD133 epitopes
|
|
US20110262477A1
(en)
|
2008-10-06 |
2011-10-27 |
University Of Chicago |
Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
|
|
CN102223894A
(zh)
*
|
2008-11-21 |
2011-10-19 |
迈阿密大学 |
用于产生粘膜和系统免疫的hiv/siv疫苗
|
|
JP2012514476A
(ja)
|
2009-01-08 |
2012-06-28 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イェシバ ユニバーシティ，ア ディビジョン オブ イェシバ ユニバーシティ |
細胞壁結合セラミド様糖脂質による細菌ワクチンおよびその使用
|
|
HRP20160274T1
(hr)
|
2009-04-03 |
2016-04-08 |
University Of Chicago |
Pripravci i metode vezane za varijante proteina a (spa)
|
|
ES2618573T3
(es)
|
2009-05-07 |
2017-06-21 |
ImmunoCellular Therapeutics,Ltd |
Epítopos de CD133
|
|
WO2011025572A1
(en)
|
2009-08-26 |
2011-03-03 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
|
|
US8075895B2
(en)
|
2009-09-22 |
2011-12-13 |
Janssen Pharmaceutica N.V. |
Identification of antigenic peptides from multiple myeloma cells
|
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
US8808699B2
(en)
|
2010-04-05 |
2014-08-19 |
The University Of Chicago |
Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
|
|
CA2797868C
(en)
|
2010-05-14 |
2023-06-20 |
The General Hospital Corporation |
Compositions and methods of identifying tumor specific neoantigens
|
|
EP2588120B1
(de)
|
2010-07-02 |
2017-11-15 |
The University of Chicago |
Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
|
|
US9095540B2
(en)
|
2010-09-09 |
2015-08-04 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
|
AU2011319727B2
(en)
|
2010-10-27 |
2016-06-30 |
Baylor College Of Medicine |
Chimeric CD27 receptors for redirecting T cells to CD70-positive malignancies
|
|
AU2012230780B2
(en)
|
2011-03-23 |
2016-10-27 |
Fred Hutchinson Cancer Center |
Method and compositions for cellular immunotherapy
|
|
EP2505640A1
(de)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
|
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
|
WO2013003579A1
(en)
|
2011-06-29 |
2013-01-03 |
Immunotope, Inc. |
Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
|
|
US9624284B2
(en)
|
2011-09-13 |
2017-04-18 |
Immunotope, Inc. |
Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
|
|
ES2795023T3
(es)
|
2011-09-16 |
2020-11-20 |
Baylor College Medicine |
Reconocimiento específico del microambiente tumoral mediante el uso de células NKT manipuladas
|
|
WO2013049856A2
(en)
|
2011-09-30 |
2013-04-04 |
Hare Joshue M |
Renal stem cells isolated from kidney
|
|
HRP20201127T1
(hr)
|
2012-04-26 |
2020-11-27 |
University Of Chicago |
Antigeni stafilokokne koagulaze i metode primjene istih
|
|
ES2949648T3
(es)
|
2012-12-20 |
2023-10-02 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
|
US20140234351A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
|
JP6702855B2
(ja)
|
2013-04-07 |
2020-06-03 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
個別化された新生物ワクチンの組成物及び方法
|
|
ES2828982T3
(es)
|
2013-05-14 |
2021-05-28 |
Univ Texas |
Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
CN120695169A
(zh)
|
2013-12-20 |
2025-09-26 |
博德研究所 |
使用新抗原疫苗的联合疗法
|
|
US10155036B2
(en)
|
2014-02-28 |
2018-12-18 |
Emergex Vaccines Holding Ltd. |
MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
|
|
EP3134437A1
(de)
|
2014-04-23 |
2017-03-01 |
Board of Regents, The University of Texas System |
Chimäre antigenrezeptoren (car) zur verwendung in der therapie und verfahren zur herstellung davon
|
|
MA39867A
(fr)
|
2014-04-23 |
2017-03-01 |
Juno Therapeutics Inc |
Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
|
|
KR20160145186A
(ko)
|
2014-04-24 |
2016-12-19 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
|
|
JP6694875B2
(ja)
|
2014-05-15 |
2020-05-20 |
ナショナル ユニヴァーシティ オブ シンガポール |
改変ナチュラルキラー細胞及びその使用
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
AU2015336029B2
(en)
|
2014-10-20 |
2021-07-22 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
|
CA2964785A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
FI3757206T3
(fi)
|
2014-11-05 |
2024-06-19 |
Juno Therapeutics Inc |
Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
|
|
CN107206025A
(zh)
|
2014-12-03 |
2017-09-26 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的方法和组合物
|
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
ES2845727T3
(es)
|
2015-02-06 |
2021-07-27 |
Heat Biologics Inc |
Vector que coexpresa una vacuna y moléculas coestimuladoras
|
|
EP3851523A1
(de)
|
2015-03-11 |
2021-07-21 |
Board Of Regents, The University Of Texas System |
Transposasepolypeptide und verwendungen davon
|
|
WO2016154585A1
(en)
|
2015-03-26 |
2016-09-29 |
Charles Sentman |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
|
JP6925980B2
(ja)
|
2015-05-13 |
2021-08-25 |
アジェナス インコーポレイテッド |
がんの処置および予防のためのワクチン
|
|
EP3297660A2
(de)
|
2015-05-20 |
2018-03-28 |
The Broad Institute Inc. |
Gemeinsam genutzte neoantigene
|
|
EP3303586A1
(de)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Zusammensetzung und verfahren zur regulierung von inhibitorischen wechselwirkungen in gentechnisch veränderten zellen
|
|
TWI750122B
(zh)
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
JP2018532386A
(ja)
|
2015-09-09 |
2018-11-08 |
イミューン デザイン コーポレイション |
Ｎｙ−ｅｓｏ−１特異的ｔｃｒおよびそれらの使用方法
|
|
US11078251B2
(en)
|
2015-09-18 |
2021-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
|
|
EP3352791B1
(de)
|
2015-09-24 |
2019-10-30 |
AbVitro LLC |
Hiv-antikörperzusammensetzungen und verfahren zur verwendung
|
|
AU2016326734B2
(en)
|
2015-09-25 |
2022-07-07 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
|
US11365391B2
(en)
|
2015-09-28 |
2022-06-21 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
WO2017055273A1
(en)
|
2015-09-28 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
|
|
WO2017055326A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
WO2017055324A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cells of monocytic origin in a tissue sample
|
|
WO2017055319A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of b cells in a tissue sample
|
|
WO2017055327A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of endothelial cells in a tissue sample
|
|
WO2017055320A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
|
|
WO2017055321A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of fibroblasts in a tissue sample
|
|
WO2017055325A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of nk cells in a tissue sample
|
|
WO2017055322A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of neutrophils in a tissue sample
|
|
WO2017068425A1
(en)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
CA3002745A1
(en)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
RU2021134624A
(ru)
|
2015-10-22 |
2022-03-15 |
Джуно Терапьютикс Гмбх |
Способы, наборы, средства и устройства для трансдукции
|
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
WO2017096327A2
(en)
|
2015-12-03 |
2017-06-08 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against cell therapies
|
|
WO2017096329A1
(en)
|
2015-12-03 |
2017-06-08 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
EP3384294B1
(de)
|
2015-12-04 |
2021-10-13 |
Juno Therapeutics, Inc. |
Verfahren und zusammensetzungen in zusammenhang mit zelltherapieassoziierter toxizität
|
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
|
EP3430548A1
(de)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Verfahren zur bestimmung der dosierung eines therapeutikums und verwandte behandlungen
|
|
MA71266A
(fr)
|
2016-03-22 |
2025-04-30 |
Seattle Children's Hospital(DBA Seattle Children's Research Institute) |
Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
|
KR20190038479A
(ko)
|
2016-05-06 |
2019-04-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 및 그의 제조방법
|
|
CA3026453A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
CA3024725A1
(en)
|
2016-06-06 |
2017-12-14 |
Juno Therapeutics, Inc. |
Methods for the treatment of b cell malignancies using adoptive cell therapy
|
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
|
CN109937364B
(zh)
|
2016-06-27 |
2022-12-02 |
朱诺治疗学股份有限公司 |
Mhc-e限制性表位、结合分子以及相关方法和用途
|
|
WO2018011166A2
(en)
|
2016-07-12 |
2018-01-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for quantifying the population of myeloid dendritic cells in a tissue sample
|
|
EP3269739A1
(de)
|
2016-07-15 |
2018-01-17 |
OGD2 Pharma |
Humanisierter antikörper gegen o-acetyliertes gd2-gangliosid (oacgd2)
|
|
EP3491022B1
(de)
|
2016-07-29 |
2025-09-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
|
|
AU2017301880C1
(en)
|
2016-07-29 |
2022-04-21 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
US11666649B2
(en)
|
2016-10-11 |
2023-06-06 |
University Of Miami |
Vectors and vaccine cells for immunity against Zika virus
|
|
SG11201903282TA
(en)
|
2016-10-13 |
2019-05-30 |
Juno Therapeutics Inc |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
|
US20190298772A1
(en)
|
2016-11-03 |
2019-10-03 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell-based therapy and a btk inhibitor
|
|
CA3045323A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
CN110248678A
(zh)
|
2016-12-03 |
2019-09-17 |
朱诺治疗学股份有限公司 |
调节car-t细胞的方法
|
|
CA3045339A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
|
|
CN110290807B
(zh)
|
2016-12-03 |
2024-06-14 |
朱诺治疗学股份有限公司 |
确定car-t细胞给药的方法
|
|
JP2019536461A
(ja)
|
2016-12-05 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法のための操作細胞の産生
|
|
JP7429338B2
(ja)
|
2017-01-10 |
2024-02-08 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のエピジェネティック解析
|
|
US11517627B2
(en)
|
2017-01-20 |
2022-12-06 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
EP3589654A1
(de)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper mit spezifität gegen nectin-4 und verwendungen davon
|
|
KR102746901B1
(ko)
|
2017-03-03 |
2024-12-26 |
옵시디안 테라퓨틱스, 인크. |
Cd19 조성물 및 면역요법을 위한 방법
|
|
JP7660343B2
(ja)
|
2017-03-03 |
2025-04-11 |
オブシディアン セラピューティクス， インコーポレイテッド |
免疫療法のための組成物及び方法
|
|
JP7277388B2
(ja)
|
2017-03-15 |
2023-05-18 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
方法
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
KR102660336B1
(ko)
|
2017-03-27 |
2024-04-26 |
내셔널 유니버시티 오브 싱가포르 |
절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
|
|
US11548930B2
(en)
|
2017-04-04 |
2023-01-10 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
|
EP3385373A1
(de)
|
2017-04-05 |
2018-10-10 |
Centro de Neurociências e Biologia Celular |
Zusammensetzungen zur umprogrammierung von zellen in dendritischen zellen oder antigen-präsentierende zellen, verfahren und verwendungen davon
|
|
WO2018185709A1
(en)
|
2017-04-05 |
2018-10-11 |
Centro De Neurociencias E Biologia Celular |
Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
|
|
WO2018187791A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
|
MA49288A
(fr)
|
2017-04-27 |
2020-03-04 |
Juno Therapeutics Gmbh |
Reactifs particulaires oligomères et leurs méthodes d'utilisation
|
|
US20200078404A1
(en)
|
2017-05-01 |
2020-03-12 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
JP7791642B2
(ja)
|
2017-05-24 |
2025-12-24 |
ノバルティス アーゲー |
抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
|
WO2018223098A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
|
SG11201912455VA
(en)
|
2017-06-20 |
2020-01-30 |
Inst Curie |
Immune cells defective for suv39h1
|
|
CN110914295B
(zh)
|
2017-06-28 |
2024-08-09 |
里珍纳龙药品有限公司 |
抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
|
|
AU2018304543A1
(en)
|
2017-07-21 |
2020-02-13 |
Berkeley Lights, Inc. |
Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated T cells, and uses thereof
|
|
MX2020001491A
(es)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Metodos y composiciones para preparar celulas geneticamente modificadas.
|
|
WO2019032927A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
|
|
US20210071258A1
(en)
|
2017-09-01 |
2021-03-11 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
|
|
WO2019054865A1
(en)
|
2017-09-14 |
2019-03-21 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
T-cell based immunotherapy
|
|
MA50613A
(fr)
|
2017-10-03 |
2020-08-12 |
Editas Medicine Inc |
Molécules de liaison spécifique à l'hpv
|
|
BR112020008565A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
processo para a produção de uma composição de célula t
|
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
EP4512823A3
(de)
|
2017-11-01 |
2025-05-14 |
Juno Therapeutics, Inc. |
Verfahren zur erzeugung therapeutischer zusammensetzungen aus manipulierten zellen
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
MX2020004572A
(es)
|
2017-11-01 |
2020-10-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
KR20200099137A
(ko)
|
2017-11-06 |
2020-08-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법 및 감마 세크레타제 억제제의 조합
|
|
JP7271539B2
(ja)
|
2017-11-14 |
2023-05-11 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
リンホトキシンアルファ遺伝子について遺伝的に改変された調節性ｔ細胞及びその使用
|
|
EP3716980A1
(de)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Verfahren zur dosieren und modulierung von genetisch veränderten zellen
|
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
|
AU2018379094B2
(en)
|
2017-12-08 |
2025-09-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
KR20200110745A
(ko)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
|
|
KR102805915B1
(ko)
|
2018-01-12 |
2025-05-15 |
주식회사 큐로셀 |
이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
|
|
CN120154716A
(zh)
|
2018-01-22 |
2025-06-17 |
恩多塞特公司 |
Car t细胞的使用方法
|
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
|
US11464800B2
(en)
|
2018-02-09 |
2022-10-11 |
Immatics US, Inc. |
Methods for manufacturing T cells
|
|
US12258381B2
(en)
|
2018-02-09 |
2025-03-25 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
DE102018108996B4
(de)
|
2018-02-09 |
2021-10-21 |
Immatics US, Inc. |
Verfahren zur Herstellung autologer T-Zellen
|
|
CN111918661A
(zh)
|
2018-02-21 |
2020-11-10 |
得克萨斯大学体系董事会 |
用于活化和扩增自然杀伤细胞的方法及其用途
|
|
CA3091671A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents,The University Of Texas System |
Universal antigen presenting cells and uses thereof
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019175381A1
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
EP3765053A2
(de)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigene peptide aus urocortin 3 und verwendungen davon zur diagnose und behandlung von typ-1-diabetes
|
|
US11413336B2
(en)
|
2018-03-23 |
2022-08-16 |
Board Of Regents, The University Of Texas System |
Coccidioides antigens and methods of their use
|
|
CN112055717B
(zh)
|
2018-04-02 |
2024-04-26 |
新加坡国立大学 |
用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
|
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
JP7630280B2
(ja)
|
2018-04-05 |
2025-02-17 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
|
|
US11065317B2
(en)
|
2018-04-26 |
2021-07-20 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
MX2020011527A
(es)
|
2018-05-03 |
2021-02-26 |
Juno Therapeutics Inc |
Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
|
|
AU2019269601A1
(en)
|
2018-05-17 |
2020-11-26 |
Regents Of The University Of Minnesota |
Drug-resistant immune cells and methods of use thereof
|
|
EP3806888B1
(de)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
|
|
MA69412B1
(fr)
|
2018-07-19 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations
|
|
IL280659B2
(en)
|
2018-08-09 |
2024-11-01 |
Juno Therapeutics Inc |
Processes for generating engineered cells and compositions thereof
|
|
WO2020033916A1
(en)
|
2018-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
|
AU2019329984A1
(en)
|
2018-08-28 |
2021-03-11 |
Fred Hutchinson Cancer Center |
Methods and compositions for adoptive T cell therapy incorporating induced notch signaling
|
|
CN112601758A
(zh)
|
2018-08-29 |
2021-04-02 |
新加坡国立大学 |
特异性刺激经基因修饰免疫细胞的存活和扩增的方法
|
|
WO2020043899A1
(en)
|
2018-08-31 |
2020-03-05 |
Invectys |
Chimeric antigen receptors against multiple hla-g isoforms
|
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
|
WO2020051766A1
(zh)
|
2018-09-11 |
2020-03-19 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
|
CA3112813A1
(en)
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
JP2022512714A
(ja)
|
2018-10-18 |
2022-02-07 |
バークレー ライツ，インコーポレイテッド |
プロト抗原提示合成表面、活性化ｔ細胞及びそれらの使用
|
|
KR102933479B1
(ko)
|
2018-10-23 |
2026-03-04 |
리제너론 파아마슈티컬스, 인크. |
Ny-eso-1 t 세포 수용체 및 이의 사용 방법
|
|
CN113227358A
(zh)
|
2018-10-31 |
2021-08-06 |
朱诺治疗学有限公司 |
选择并刺激细胞的方法及用于所述方法的设备
|
|
AU2019372331A1
(en)
|
2018-11-01 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
MA54079A
(fr)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
|
|
MX2021005021A
(es)
|
2018-11-06 |
2021-08-11 |
Juno Therapeutics Inc |
Proceso para producir celulas t geneticamente modificadas.
|
|
KR20210111247A
(ko)
|
2018-11-08 |
2021-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 및 ｔ 세포 조절을 위한 방법 및 조합
|
|
KR20210104713A
(ko)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
|
|
FI3886875T3
(fi)
|
2018-11-30 |
2024-07-23 |
Juno Therapeutics Inc |
Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
|
|
BR112021010120A2
(pt)
|
2018-11-30 |
2021-08-31 |
Juno Therapeutics, Inc. |
Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
|
|
US12227551B2
(en)
|
2018-12-11 |
2025-02-18 |
Obsidian Therapeutics, Inc. |
Membrane bound IL12 compositions and methods for tunable regulation
|
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
|
US12319930B2
(en)
|
2019-01-24 |
2025-06-03 |
Valorisation Hsj, Limited Partnership |
Cell specific transcriptional regulatory sequences and uses thereof
|
|
AU2020215576A1
(en)
|
2019-01-29 |
2021-07-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
|
|
SG11202109057XA
(en)
|
2019-03-05 |
2021-09-29 |
Nkarta Inc |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
SG11202109172TA
(en)
|
2019-03-08 |
2021-09-29 |
Obsidian Therapeutics Inc |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
|
DE102019108125B4
(de)
|
2019-03-28 |
2022-02-03 |
Immatics US, Inc. |
Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
|
|
US20200297768A1
(en)
|
2019-03-19 |
2020-09-24 |
Immatics US, Inc. |
Cd28 t cell cultures, compositions, and methods of using thereof
|
|
CN113811329B
(zh)
|
2019-04-19 |
2025-10-14 |
天科雅生物科技有限公司 |
抗pd-1抗体和其用途
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
CA3139981A1
(en)
|
2019-05-14 |
2020-11-19 |
The University Of Chicago |
Methods and compositions comprising staphylococcus protein a (spa) variants
|
|
WO2020229546A1
(en)
|
2019-05-14 |
2020-11-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
|
JP2022537670A
(ja)
|
2019-06-12 |
2022-08-29 |
オブシディアン セラピューティクス， インコーポレイテッド |
Ｃａ２の組成物および調整可能な制御方法
|
|
KR20220034782A
(ko)
|
2019-06-12 |
2022-03-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
|
|
EP3983537A1
(de)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
|
|
EP3994245A1
(de)
|
2019-07-05 |
2022-05-11 |
Case Western Reserve University |
Priming-medium und verfahren für stammzellenkultur und -therapie
|
|
US12319745B2
(en)
|
2019-07-16 |
2025-06-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for CD38 and uses thereof
|
|
US20220251572A1
(en)
|
2019-07-23 |
2022-08-11 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
CA3147903A1
(en)
|
2019-07-24 |
2021-01-28 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
|
CN114555112A
(zh)
|
2019-08-22 |
2022-05-27 |
朱诺治疗学股份有限公司 |
T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
EP4028413A1
(de)
|
2019-09-10 |
2022-07-20 |
Obsidian Therapeutics, Inc. |
Ca2-il15-fusionsproteine zur abstimmbaren regulierung
|
|
US12528882B2
(en)
|
2019-09-13 |
2026-01-20 |
The University Of Chicago |
Methods and compositions for treating staphylococcal infections
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
JP2022552270A
(ja)
|
2019-10-09 |
2022-12-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
変異ｃｘｃｒ４を発現するように改変された又は部分的に欠失されたｔ細胞及びその使用
|
|
EP4045663A2
(de)
|
2019-10-16 |
2022-08-24 |
Umoja Biopharma, Inc. |
Retroviraler vektor zur universellen rezeptortherapie
|
|
BR112022008023A2
(pt)
|
2019-10-30 |
2022-07-12 |
Juno Therapeutics Gmbh |
Dispositivos de seleção e/ou estimulação de células e métodos de uso
|
|
JP2023500671A
(ja)
|
2019-11-06 |
2023-01-10 |
ベイラー カレッジ オブ メディスン |
がんのｔ細胞治療のための細胞傷害性エフェクターメモリーｔ細胞の産生方法
|
|
US20220401483A1
(en)
|
2019-11-07 |
2022-12-22 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
|
|
WO2021105234A1
(en)
|
2019-11-25 |
2021-06-03 |
Asgard Therapeutics Ab |
Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
|
|
EP4070097A1
(de)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Verfahren in zusammenhang mit toxizität und ansprechen bei einer zelltherapie zur behandlung von b-zell-malignitäten
|
|
US12577324B2
(en)
|
2019-12-09 |
2026-03-17 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity to HER4 and uses thereof
|
|
CA3163838A1
(en)
|
2020-01-08 |
2021-07-15 |
Vipin Suri |
Compositions and methods for tunable regulation of transcription
|
|
PH12022551857A1
(en)
|
2020-01-24 |
2024-01-03 |
Regeneron Pharma |
Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
|
|
BR112022014501A2
(pt)
|
2020-01-24 |
2022-09-20 |
Juno Therapeutics Inc |
Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
|
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 형질도입 방법
|
|
IL295381A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
|
|
EP4110823A1
(de)
|
2020-02-26 |
2023-01-04 |
A2 Biotherapeutics, Inc. |
Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
|
|
CN115916963A
(zh)
|
2020-03-27 |
2023-04-04 |
门德斯有限公司 |
白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
|
|
US20210322471A1
(en)
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
|
EP4142723A2
(de)
|
2020-04-28 |
2023-03-08 |
Juno Therapeutics, Inc. |
Kombination aus bcma-gerichteter t-zelltherapie und einer immunmodulatorischen verbindung
|
|
CA3175491A1
(en)
|
2020-05-05 |
2021-11-11 |
David DILILLO |
Car comprising cd28 zeta and cd3 zeta
|
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
|
EP4150640A1
(de)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Verfahren zur identifizierung von merkmalen im zusammenhang mit klinischer reaktion und verwendungen davon
|
|
BR112022024027A2
(pt)
|
2020-05-27 |
2023-02-07 |
Antion Biosciences Sa |
Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
|
|
JP2023530919A
(ja)
|
2020-06-17 |
2023-07-20 |
ヤンセン バイオテツク，インコーポレーテツド |
多能性幹細胞の製造のための材料及び方法
|
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
|
|
AU2021302958A1
(en)
|
2020-06-30 |
2023-02-16 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
CN116323656A
(zh)
|
2020-07-16 |
2023-06-23 |
优莫佳生物制药股份有限公司 |
门控衔接子靶向受体
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
EP4188395A1
(de)
|
2020-07-30 |
2023-06-07 |
Institut Curie |
Socs1-deffiziente immunzellen
|
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
WO2022040444A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
AU2021329375A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
CA3188862A1
(en)
|
2020-08-20 |
2022-02-24 |
Carl Alexander Kamb |
Compositions and methods for treating mesothelin positive cancers
|
|
US20220056411A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
|
US20230272068A1
(en)
|
2020-08-21 |
2023-08-31 |
12343096 Canada Inc. |
Modular assembly receptors and uses thereof
|
|
WO2022047419A1
(en)
|
2020-08-31 |
2022-03-03 |
City Of Hope |
Novel cell lines, methods of producing natural killer cells and uses thereof
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
|
WO2022074098A1
(en)
|
2020-10-08 |
2022-04-14 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Method for the identification of cancer neoantigens
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
CA3196677A1
(en)
|
2020-11-05 |
2022-05-12 |
Erik Hans MANTING |
Use of tumor-independent antigens in immunotherapies
|
|
EP4251282A1
(de)
|
2020-11-27 |
2023-10-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
US12397055B2
(en)
|
2021-01-22 |
2025-08-26 |
Mendus B.V. |
Methods of tumor vaccination
|
|
IL304904A
(en)
|
2021-02-01 |
2023-10-01 |
St Phi Therapeutics Co Ltd |
Target protein degradation system and its use
|
|
CA3207958A1
(en)
|
2021-02-16 |
2022-08-25 |
Julyun OH |
Compositions and methods for treating her2 positive cancers
|
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
EP4314814A1
(de)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Verfahren zur bestimmung der wirksamkeit einer therapeutischen zellzusammensetzung
|
|
BR112023019847A2
(pt)
|
2021-03-29 |
2023-11-07 |
Juno Therapeutics Inc |
Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
|
|
JP2024513054A
(ja)
|
2021-03-29 |
2024-03-21 |
ジュノー セラピューティクス インコーポレイテッド |
リンパ腫の治療のためのｃａｒ ｔ細胞療法および免疫調節化合物の組合せ
|
|
IL307612A
(en)
|
2021-04-16 |
2023-12-01 |
Celgene Corp |
Combined therapies with BCMA-directed T-cell therapy
|
|
CA3217914A1
(en)
|
2021-05-04 |
2022-11-10 |
Kevin BRAY |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
|
KR20240018454A
(ko)
|
2021-05-06 |
2024-02-13 |
주노 테라퓨틱스 게엠베하 |
T 세포의 자극 및 형질도입 방법
|
|
WO2022248602A1
(en)
|
2021-05-25 |
2022-12-01 |
Institut Curie |
Myeloid cells overexpressing bcl2
|
|
WO2023006120A1
(zh)
|
2021-07-30 |
2023-02-02 |
羿尊生物医药（浙江）有限公司 |
通用型t细胞及其应用
|
|
WO2023044488A1
(en)
|
2021-09-20 |
2023-03-23 |
Immatics US, Inc. |
Monocyte depletion of t cells populations for t-cell therapy
|
|
KR20240112994A
(ko)
|
2021-11-03 |
2024-07-19 |
셀진 코포레이션 |
골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4433512A4
(de)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
|
|
CA3244649A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
IMMUNE CELLS WITH INACTIVATED SUV39H1 AND MODIFIED TCR
|
|
JP2025504882A
(ja)
|
2022-01-21 |
2025-02-19 |
ムネモ・セラピューティクス |
Ｒｎａによるｓｕｖ３９ｈ１発現の調節
|
|
AU2023217968A1
(en)
|
2022-02-09 |
2024-09-26 |
Janssen Biotech, Inc. |
Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
|
|
US20250099584A1
(en)
|
2022-02-18 |
2025-03-27 |
Institut National de la Santé et de la Recherche Médicale |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
|
AU2023225954A1
(en)
|
2022-02-22 |
2024-09-05 |
Deka Biosciences, Inc. |
Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins
|
|
IL314801A
(en)
|
2022-02-22 |
2024-10-01 |
Juno Therapeutics Inc |
Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
|
|
US20250179170A1
(en)
|
2022-03-08 |
2025-06-05 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(de)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
|
EP4543923A1
(de)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Behandlungsverfahren für die zweite therapie von cd19-gezielten car-t-zellen
|
|
US20250382640A1
(en)
|
2022-06-29 |
2025-12-18 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
WO2024019984A1
(en)
|
2022-07-18 |
2024-01-25 |
Cargo Therapeutics, Inc. |
Cytokine receptor switch polypeptides and uses thereof
|
|
JP2025525612A
(ja)
|
2022-07-22 |
2025-08-05 |
ヤンセン バイオテツク，インコーポレーテツド |
エフェクター免疫細胞への遺伝的命令の増強された移入
|
|
KR20250047766A
(ko)
|
2022-08-05 |
2025-04-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
|
|
CN120435310A
(zh)
|
2022-08-26 |
2025-08-05 |
朱诺治疗学股份有限公司 |
对δ样配体3（DLL3）具有特异性的抗体和嵌合抗原受体
|
|
EP4580658A1
(de)
|
2022-08-31 |
2025-07-09 |
Institut National de la Santé et de la Recherche Médicale |
Verfahren zur erzeugung effizienterer car-t-zellen
|
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
JP2025531850A
(ja)
|
2022-09-08 |
2025-09-25 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
US20260077045A1
(en)
|
2022-10-07 |
2026-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
WO2024091944A1
(en)
|
2022-10-25 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Split receptor switch polypeptides and uses thereof
|
|
WO2024092126A1
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for improved immunotherapies
|
|
WO2024092092A2
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for allogeneic immunotherapies
|
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
|
EP4611798A1
(de)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Behandlungsverfahren mit t-zelltherapie und immunmodulatorischer mittelerhaltungstherapie
|
|
WO2024123760A1
(en)
|
2022-12-05 |
2024-06-13 |
Cargo Therapeutics, Inc. |
Multiplex cell selection compositions and uses thereof
|
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
|
WO2024168276A2
(en)
|
2023-02-09 |
2024-08-15 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
EP4687959A1
(de)
|
2023-03-24 |
2026-02-11 |
Cornell University |
Verwendung von t-zellen aus tumordränierenden lymphknoten zur chimären antigenrezeptor(car)-t-zelltherapie zur behandlung von krebs
|
|
CN121311765A
(zh)
|
2023-04-18 |
2026-01-09 |
朱诺治疗学股份有限公司 |
评估治疗性细胞组合物的效力的细胞毒性测定
|
|
WO2024223877A1
(en)
|
2023-04-26 |
2024-10-31 |
Institut National de la Santé et de la Recherche Médicale |
Method for modulating the differentiation and functions of human dendritic cells
|
|
CN121335919A
(zh)
|
2023-05-25 |
2026-01-13 |
瑞泽恩制药公司 |
结合呈递的hpv16、mart1、cmv、ebv或流感肽的t细胞受体
|
|
WO2025029930A1
(en)
|
2023-07-31 |
2025-02-06 |
Legend Biotech Ireland Limited |
Cells overexpressing cd31 and methods of use thereof
|
|
WO2025049972A1
(en)
|
2023-09-01 |
2025-03-06 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025085680A1
(en)
|
2023-10-17 |
2025-04-24 |
Cargo Therapeutics, Inc. |
Methods for manufacturing car t cells
|
|
WO2025082603A1
(en)
|
2023-10-18 |
2025-04-24 |
Institut Curie |
Engineered immune cells overexpressing cd74 molecule
|
|
WO2025090978A1
(en)
|
2023-10-26 |
2025-05-01 |
Cargo Therapeutics, Inc. |
Modified immune effector cells
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
WO2025125363A1
(en)
|
2023-12-11 |
2025-06-19 |
Institut National de la Santé et de la Recherche Médicale |
Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
|
|
WO2025129084A1
(en)
|
2023-12-13 |
2025-06-19 |
Umoja Biopharma, Inc. |
Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025245381A1
(en)
|
2024-05-23 |
2025-11-27 |
The Trustrees Of Dartmouth College |
Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
|
|
WO2025255030A1
(en)
|
2024-06-03 |
2025-12-11 |
Cornell University |
Interferon gamma responsive chimeric t cell costimulatory receptor
|
|
WO2026002973A1
(en)
|
2024-06-25 |
2026-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Host immune cells engineered to overexpress a foxk1 polypeptide
|
|
WO2026035951A2
(en)
|
2024-08-07 |
2026-02-12 |
Legend Biotech Ireland Limited |
Cells overexpressing cd43 and methods of use thereof
|
|
WO2026055226A1
(en)
|
2024-09-03 |
2026-03-12 |
Legend Biotech Ireland Limited |
Cells overexpressing b3gnt2 and methods of use thereof
|